Department of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.
Department of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan.
Biomed Pharmacother. 2018 Oct;106:686-691. doi: 10.1016/j.biopha.2018.07.012. Epub 2018 Jul 11.
We previously showed that an alkyl-ether analog of lysophosphatidic acid, AGP (alkyl-glycerophosphate), accumulates in human atherosclerotic plaques and is a potent agonist of peroxisome proliferator-activated receptor-gamma (PPARγ). On the other hand, cyclic phosphatidic acid (cPA), similar in structure to AGP, can negatively regulate PPARγ. However, in this study, cPA had no effect on the expression and secretion of C-C motif chemokine 2 (CCL-2), a chemokine that is also linked to inflammatory responses and atherosclerosis. We showed that AGP enhances CCL-2 mRNA expression and secretion in a dose-dependent manner. Furthermore, oxidative stress plays a major role in the pathology of cardiovascular diseases; we showed that AGP triggers ROS generation and lipid peroxidation and that ROS and 8-isoprostane generation can be suppressed by a PPARγ antagonist. These results suggest that an imbalance of the PPARγ agonist-antagonist equilibrium is involved in changes in cellular functions, including ROS generation and lipid peroxidation.
我们之前的研究表明,溶血磷脂酸的烷基醚类似物 AGP(烷基甘油磷酸)在人类动脉粥样硬化斑块中积累,并且是过氧化物酶体增殖物激活受体-γ(PPARγ)的有效激动剂。另一方面,结构上与 AGP 相似的环状磷脂酸 (cPA) 可以负调控 PPARγ。然而,在这项研究中,cPA 对趋化因子 C-C 基序 2 (CCL-2) 的表达和分泌没有影响,CCL-2 也是与炎症反应和动脉粥样硬化有关的趋化因子。我们发现 AGP 以剂量依赖的方式增强 CCL-2 mRNA 的表达和分泌。此外,氧化应激在心血管疾病的病理学中起着主要作用;我们发现 AGP 触发 ROS 的产生和脂质过氧化,而 ROS 和 8-异前列腺素的产生可以被 PPARγ 拮抗剂抑制。这些结果表明,PPARγ 激动剂-拮抗剂平衡的失衡参与了包括 ROS 产生和脂质过氧化在内的细胞功能的变化。